Breast Cancer Index (BCI) validation studies included both women treated with aromatase inhibitors (AI) and women treated with tamoxifen (Tam). The three validation studies included patients treated with Tam only (Stockholm), either anastrozole or Tam (ATAC), and Tam with a transition to letrozole (MA.17).
For more information, visit: http://www.breastcancerindex.com
http://www.answersbeyond5.com
http://www.twitter.com/answersbyond5